Restless Legs Syndrome (RLS) is a pervasive, sleep-related movement disorder significantly impacting approximately 3% of US adults to a clinically relevant extent. Patients experience an overwhelming urge to move their limbs, typically the legs, often with unpleasant sensations like tingling or achiness. Immobility provokes these symptoms; conversely, movement quickly relieves them. Furthermore, symptoms are generally worst in the evening or at night. RLS can lead to significant difficulty falling asleep, staying asleep, or returning to sleep. Therefore, clinicians must correctly diagnose and manage this condition.
According to population-based studies, about 8% of US adults experience RLS symptoms annually. Only 3% experience moderately or severely distressing symptoms at least twice a week. Patients with RLS face an impaired quality of life. Moreover, they have elevated rates of cardiovascular disease (29.6%), depression (30.4%), and suicidal ideation or self-harm (0.35 cases/1000 person-years). Recognizing the high comorbidity burden is essential for comprehensive care.
Diagnosis and Associated Risk Factors
A clinical history is sufficient for diagnosis; consequently, polysomnography is not routinely recommended. RLS is common among patients with multiple sclerosis (27.5%), end-stage kidney disease (24%), or iron deficiency anemia (23.9%). Additionally, it frequently occurs during pregnancy, particularly in the third trimester (22%). The disorder is also linked to peripheral neuropathy (21.5%) and Parkinson disease (20%). Other critical risk factors include a family history of RLS, northern European descent, and older age (≥65 years). Note that the female-to-male sex ratio is 2:1.
Management of Restless Legs Syndrome
Effective management begins with addressing secondary causes. If a patient’s serum ferritin level is ≤100 ng/mL or transferrin saturation is less than 20%, iron supplementation is necessary. You should initiate ferrous sulfate (325-650 mg daily or every other day) or intravenous iron (1000 mg) immediately. Clinicians should also discontinue medications associated with RLS whenever possible. For instance, you should stop serotonergic antidepressants, dopamine antagonists, and centrally acting H1 antihistamines (like diphenhydramine). After addressing non-pharmacologic and secondary causes, gabapentinoids represent first-line pharmacologic therapy. These include gabapentin, gabapentin enacarbil, and pregabalin. Furthermore, clinical trials show approximately 70% of patients treated with gabapentinoids experienced much or very much improved RLS symptoms compared to only about 40% with placebo. Low-dose dopamine agonists are another option, although augmentation is a concern. Therefore, careful patient selection is paramount.
Frequently Asked Questions
Q1: What are the primary diagnostic criteria for Restless Legs Syndrome?
Restless Legs Syndrome is diagnosed based on clinical history alone. The core features include an overwhelming urge to move the limbs (typically legs) often accompanied by unpleasant sensations. These symptoms begin or worsen during rest, are relieved by movement, and are most severe in the evening or at night. Polysomnography is generally not needed for diagnosis.
Q2: Which comorbidities are frequently associated with RLS?
Patients with RLS have elevated rates of several serious comorbidities. These include cardiovascular disease, depression, and suicidal ideation. Moreover, RLS is highly prevalent in individuals with multiple sclerosis, end-stage kidney disease, iron deficiency anemia, peripheral neuropathy, and Parkinson disease.
Q3: What is the first-line pharmacologic treatment for RLS?
First-line pharmacologic therapy involves gabapentinoids, such as gabapentin, gabapentin enacarbil, or pregabalin. However, addressing iron deficiency (serum ferritin ≤100 ng/mL or transferrin saturation <20%) with iron supplementation and discontinuing exacerbating medications (e.g., serotonergic antidepressants) are crucial initial steps.
References
- Winkelman JW et al. Restless Legs Syndrome: A Review. JAMA. 2026 Jan 21. doi: 10.1001/jama.2025.23247. PMID: 41563785.
- The Management of Restless Legs Syndrome: An Updated Algorithm. RLS Foundation.
- Treatment of Restless Legs Syndrome in Adults: Practice Guideline. Medical Dialogues.
- Restless Legs Syndrome: Causes, Symptoms & Treatment. Cleveland Clinic.